FSD Pharma Inc Stock

$16.75

2.45% yesterday

Nasdaq, Aug 27, 10:07 pm CET

ISIN

CA35954B2066

Symbol

QNTM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

FSD Pharma Inc Stock price

$16.75

-181.50 91.55% 5Y

Nasdaq, Closing price Wed, Aug 27 2025

+0.40 2.45%

ISIN

CA35954B2066

Symbol

QNTM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$62.3m

Enterprise Value

$63.0m

Net debt

$740.0k

Cash

$1.5m

Shares outstanding

3.5m

Valuation (TTM | estimate)

P/E

negative | -

P/S

- | 9.0

EV/Sales

- | 8.8

EV/FCF

negative

P/B

16.6

Financial Health

Equity Ratio

Return on Equity

ROCE

-910.9%

ROIC

Debt/Equity

0.6

Financials (TTM | estimate)

Revenue

$0.0 | $8.7m

EBITDA

$-18.2m | -

EBIT

$-18.7m | -

Net Income

$-26.6m | -

Free Cash Flow

$-10.5m

EPS

$-8.8

FCF per Share

$-3.0

Short interest

2.2%

Employees

Rev per Employee

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Get Started for Free Today

FSD Pharma Inc Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a FSD Pharma Inc forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a FSD Pharma Inc forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from FSD Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	11 11	21% 21% -
- Research and Development Expense	7.22 7.22	581% 581% -
EBITDA	-18 -18	81% 81% -
- Depreciation and Amortization	0.50 0.50	6% 6% -
EBIT (Operating Income) EBIT	-19 -19	76% 76% -
Net Profit	-27 -27	223% 223% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

FSD Pharma Inc Stock News

Neutral

GlobeNewsWire

●

17 days ago

Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial

TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to innovative therapies for neurodegenerative disorders, today announces through its subsidiary, Huge Biopharma Australia Pty Ltd., that it has signed an agreement with a leading contract developme...

Neutral

GlobeNewsWire

●

20 days ago

Quantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography (PET) Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients

Ongoing Joint Clinical Study Could Pave the Way for Testing Efficacy of Quantum's Investigational MS drug, Lucid-21-302 Ongoing Joint Clinical Study Could Pave the Way for Testing Efficacy of Quantum's Investigational MS drug, Lucid-21-302

Neutral

GlobeNewsWire

●

21 days ago

Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of date of filing, and Near Elimination of Debt

Unprecedented Quarter Shows Company's Strong Financial Position and Continued Momentum with its Multiple Sclerosis Clinical Trials and unbuzzdTM Recreational Beverage and Alcohol Metabolizer Unprecedented Quarter Shows Company's Strong Financial Position and Continued Momentum with its Multiple Sclerosis Clinical Trials and unbuzzdTM Recreational Beverage and Alcohol Metabolizer

More FSD Pharma Inc News

Company Profile

FSD Pharma Inc., through its subsidiary, FV Pharma Inc., produces medical cannabis in Canada. The company focuses on the development of indoor grown pharmaceutical grade cannabis; and research and development of various cannabinoid-based treatments for various central nervous system disorders, including chronic pain, fibromyalgia, and irritable bowel syndrome. FSD Pharma Inc. has a strategic alliance agreement with SciCann Therapeutics Inc. for the production and distribution of cannabinoid-based, patent pending, and indication-specific products; and collaborative research and development agreement with Solarvest BioEnergy Inc. The company is headquartered in Cobourg, Canada.

Head office	Canada
CEO	Zeeshan Saeed
Founded	1994
Website	www.fsdpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now